Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C2509
http://purl.obolibrary.org/obo/NCIT_C2509
|
|---|---|
| Preferred Name | Hu14.18-IL2 Fusion Protein EMD 273063 |
| Definitions |
A recombinant protein consisting of the hu14.18 monoclonal antibody fused to the cytokine interleukin-2 (IL2) with potential antineoplastic activity. The monoclonal antibody portion of the hu14.18-IL2 EMD 273063 fusion protein binds to tumor cells expressing the GD2 antigen (melanoma, neuroblastoma and certain other tumors); the Fc component of the fusion protein antibody moiety and natural killer (NK) cells mediate antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cellular cytotoxicity (CDCC) towards GD2-expressing tumor cells. The localized IL2 moiety of the fusion protein stimulates NK and T-cell antitumor cellular immune responses.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A recombinant protein consisting of the hu14.18 monoclonal antibody fused to the cytokine interleukin-2 (IL2) with potential antineoplastic activity. The monoclonal antibody portion of the hu14.18-IL2 EMD 273063 fusion protein binds to tumor cells expressing the GD2 antigen (melanoma, neuroblastoma and certain other tumors); the Fc component of the fusion protein antibody moiety and natural killer (NK) cells mediate antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cellular cytotoxicity (CDCC) towards GD2-expressing tumor cells. The localized IL2 moiety of the fusion protein stimulates NK and T-cell antitumor cellular immune responses. |
|---|---|
| prefLabel | Hu14.18-IL2 Fusion Protein EMD 273063
|
| label | Hu14.18-IL2 Fusion Protein EMD 273063
|
| PDQ_Closed_Trial_Search_ID | 43349
|
| code | C2509
|
| Has_Target | |
| prefixIRI | NCIT:C2509
|
| in_subset |
See more
See less
|
| Display_Name | Hu14.18-IL2 Fusion Protein EMD 273063
|
| Preferred_Name | Hu14.18-IL2 Fusion Protein EMD 273063
|
| Contributing_Source | CTRP
|
| Maps_To | Hu14.18-IL2 Fusion Protein EMD 273063
|
| NSC Number | 721298
|
| NCI_Drug_Dictionary_ID | 43349
|
| Legacy Concept Name | Hu14_18-Interleukin-2_Fusion_Protein
|
| type | |
| ALT_DEFINITION | An anticancer drug in which hu14.18, a monoclonal antibody, is combined with interleukin-2. The monoclonal antibody binds to the cancer cells and delivers IL-2, which stimulates the immune system to destroy the cancer cells.
|
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 43349
|
| Semantic_Type |
Amino Acid, Peptide, or Protein
Pharmacologic Substance
|
| UMLS_CUI | C1529682
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |